↓ Skip to main content

Intravesical gemcitabine for non-muscle invasive bladder cancer

Overview of attention for article published in Cochrane database of systematic reviews, January 2012
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (88th percentile)
  • Good Attention Score compared to outputs of the same age and source (74th percentile)

Citations

dimensions_citation
38 Dimensions

Readers on

mendeley
111 Mendeley
citeulike
1 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Intravesical gemcitabine for non-muscle invasive bladder cancer
Published in
Cochrane database of systematic reviews, January 2012
DOI 10.1002/14651858.cd009294.pub2
Pubmed ID
Authors

Gabriel Jones, Anne Cleves, Timothy J Wilt, Malcolm Mason, Howard G Kynaston, Mike Shelley

Abstract

Intravesical immunotherapy or chemotherapy for non-muscle invasive bladder cancer is a well established treatment for preventing or delaying tumour recurrence following tumour resection. However, up to 70% of patients may fail and new intravesical agents with improved effectiveness are needed. Gemcitabine is a relatively new anticancer drug that has shown activity against bladder cancer.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 111 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Netherlands 1 <1%
India 1 <1%
Unknown 109 98%

Demographic breakdown

Readers by professional status Count As %
Student > Master 20 18%
Student > Postgraduate 14 13%
Other 12 11%
Researcher 10 9%
Student > Bachelor 8 7%
Other 23 21%
Unknown 24 22%
Readers by discipline Count As %
Medicine and Dentistry 53 48%
Nursing and Health Professions 10 9%
Pharmacology, Toxicology and Pharmaceutical Science 5 5%
Engineering 3 3%
Social Sciences 3 3%
Other 11 10%
Unknown 26 23%

Attention Score in Context

This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 May 2018.
All research outputs
#1,969,803
of 16,651,917 outputs
Outputs from Cochrane database of systematic reviews
#4,672
of 11,558 outputs
Outputs of similar age
#14,282
of 128,377 outputs
Outputs of similar age from Cochrane database of systematic reviews
#31
of 117 outputs
Altmetric has tracked 16,651,917 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 11,558 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 24.4. This one has gotten more attention than average, scoring higher than 59% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 128,377 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 117 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.